Blockade of OX40/OX40L signaling using anti‐OX40L alleviates murine lupus nephritis
European Journal of Immunology · 2024
DOI: 10.1002/eji.202350915 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2024. Verfasst von Junpeng Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China. Hauptthemen laut MEDLINE: Lupus Nephritis, OX40 Ligand, Mice, Inbred MRL lpr, Signal Transduction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Key R&D Program of China, Special Program of National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences (CIFMS).
Abstract (Originalsprache)
Genetic variants of the OX40 ligand (OX40L) locus are associated with the risk of systemic lupus erythematosus (SLE), it is unclear how the OX40L blockade delays the lupus phenotype. Therefore, we examined the effects of an anti‐OX40L antibody in MRL/Lpr mice. Next, we investigated the effect of anti‐OX40L on immunosuppression in keyhole limpet hemocyanin‐immunized C57BL/6J mice. In vitro treatment of anti‐OX40L in CD4 + T and B220 + B cells was used to explore the role of OX40L in the pathogenesis of SLE. Anti‐OX40L alleviated murine lupus nephritis, accompanied by decreased production of anti‐dsDNA and proteinuria, as well as lower frequencies of splenic T helper (Th) 1 and T‐follicular helper cells (Tfh). In keyhole limpet hemocyanin‐immunized mice, decreased levels of immunoglobulins and plasmablasts were observed in the anti‐OX40L group. Anti‐OX40L reduced the number and area of germinal centers. Compared with the control IgG group, anti‐OX40L downregulated CD4 + T‐cell differentiation into Th1 and Tfh cells and upregulated CD4 + T‐cell differentiation into regulatory T cells in vitro. Furthermore, anti‐OX40L inhibited toll‐like receptor 7‐mediated differentiation of antibody‐secreting cells and antibody production through the regulation of the SPIB‐BLIMP1‐XBP1 axis in B cells. These results suggest that OX40L is a promising therapeutic target for SLE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.
- Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
- Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China.
- Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Institute of Dermatology, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.
- Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha, China.
Förderung
- National Key R&D Program of China
- Special Program of National Natural Science Foundation of China
- CAMS Innovation Fund for Medical Sciences (CIFMS)
- Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
- National Key Research and Development Program of China
Zitieren
APA
Zhao, J., Li, L., Feng, X., Yin, H., Fan, X., Gao, C., Zhao, M., & Lu, Q. (2024). Blockade of OX40/OX40L signaling using anti‐OX40L alleviates murine lupus nephritis. European Journal of Immunology. https://doi.org/10.1002/eji.202350915
Vancouver
Zhao J, Li L, Feng X, Yin H, Fan X, Gao C, et al. Blockade of OX40/OX40L signaling using anti‐OX40L alleviates murine lupus nephritis. European Journal of Immunology. 2024. doi:10.1002/eji.202350915
BibTeX
@article{Zhao2024,
author = {Zhao, Junpeng and Li, Liming and Feng, Xiwei and Yin, Huiqi and Fan, Xinyu and Gao, Changxing and Zhao, Ming and Lu, Qianjin},
title = {Blockade of OX40/OX40L signaling using anti‐OX40L alleviates murine lupus nephritis},
journal = {European Journal of Immunology},
year = {2024},
doi = {10.1002/eji.202350915}
}
EUVIMED